v3.26.1
Consolidated income statements - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Statement [line items]        
Net sales to third parties $ 14,408 $ 14,054 $ 27,521 $ 27,287
Other revenues 543 782 954 1,169
Cost of goods sold (3,710) (3,322) (7,169) (6,549)
Gross profit 11,241 11,514 21,306 21,907
Selling, general and administration (3,241) (3,442) (6,381) (6,500)
Research and development (2,847) (2,727) (5,587) (5,093)
Other income 410 548 888 774
Other expense (813) (1,029) (1,241) (1,561)
Operating income 4,750 4,864 8,985 9,527
Loss from associated companies (2) (3) (5) (6)
Interest expense (462) (289) (805) (559)
Other financial income and expense (17) (41) (67) (24)
Income before taxes 4,269 4,531 8,108 8,938
Income taxes (1,012) (507) (1,695) (1,305)
Net income 3,257 4,024 6,413 7,633
Attributable to        
Shareholders of Novartis AG 3,264 4,041 6,420 7,647
Non-controlling interests $ (7) $ (17) $ (7) $ (14)
Basic earnings per share [abstract]        
Weighted average number of ordinary shares outstanding 1,905 1,948 1,906 1,958
Basic earnings per share $ 1.71 $ 2.07 $ 3.37 $ 3.91
Diluted earnings per share [abstract]        
Adjusted weighted average number of ordinary shares outstanding 1,914 1,960 1,915 1,970
Diluted earnings per share $ 1.71 $ 2.06 $ 3.35 $ 3.88